Dr. Dionne joined Surface Logix in October of 2008. He brings nearly 20 years of leadership experience in the biotechnology industry to the company. Prior to joining Surface Logix, Dr. Dionne was CEO of Alantos Pharmaceuticals, where he led the Company through its successful acquisition by Amgen for more than $300 million in cash. Prior to Alantos, Dr. Dionne held senior-level positions at Millennium Pharmaceuticals, including most recently Vice President of Research and Development Strategy and Vice President & General Manager: Technology Business. As Vice President of R&D Strategy, he chaired the Portfolio Development Committee responsible for advancing compounds from early development through launch. Dr. Dionne also led the Millennium/Aventis Technology Alliance, as well as the Millennium/Monsanto Agricultural Alliance, under which he spearheaded the start-up of Cereon, a wholly-owned subsidiary of Monsanto. Prior to that, Dr. Dionne was responsible for technology program management and strategic alliances. Before his tenure with Millennium, Dr. Dionne served as Head of Pre-Clinical Research & Development: Implants at ALZA Pharmaceuticals. While with ALZA, he led the development of the Duros™ family of implantable drug delivery systems and was responsible for guiding the development of Viadur™, a prostate cancer product, from concept to phase II clinical trials in less than three years. Dr. Dionne was one of four original scientists at CytoTherapeutics, Inc., a cell transplantation company. He has served as an Adjunct Professor in the Biomedical Department at Brown University. Dr. Dionne received both his Ph.D. in Chemical Engineering and his M.S. in the Program for Technology Policy from Massachusetts Institute of Technology.

At Arch, Dr. Gillis’ focus is on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. Prior to ARCH, Dr. Gillis founded Corixa Corp. (acquired by GlaxoSmithKline in July 2005), where he served as the company’s Chief Executive Officer since its inception and as its Chairman since 1999. Dr. Gillis was also a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex following its majority purchase by American Cyanamid Company and he remained a member of the Board of Directors until 1997. Immunex was acquired by Amgen Inc. in 2002. An immunologist by training, Dr. Gillis has over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors. Dr. Gillis received his B.A. from Williams College and his Ph.D. from Dartmouth College.

Mr. Madsen has 15 years of experience in developing technology companies. He most recently served as Managing Director and leader of the investment practice of Unilever Technology Ventures Advisory Company LLC, an investment advisor to Unilever Technology Ventures Fund BV, a €50 million venture fund affiliated with Unilever N.V. From 1998 to 2003 he served as a Partner of RBC Capital Partners ("RBC"), the private equity arm of the Royal Bank of Canada, where he was responsible for opening an office covering the Western Canadian market and, in 2002, for opening the RBC Life Sciences Fund's first U.S.office in San Francisco, California. At RBC, he led RBC's investments in early-stage North American healthcare companies such as Cytovax Biotechnologies, Hemosol, Inex Pharmaceuticals, Sembiosys Genetics, Idun Pharmaceuticals, Corus Pharma, Conforma Therapeutics and NeuroMed Technologies. While at RBC, Mr. Madsen also served as Chief Financial Officer of Cytovax Biotechnologies Inc., raising a private placement and taking Cytovax to its IPO in 2001. Prior to joining RBC, Mr. Madsen was Chief Financial Officer of Cyberion Networking Inc., then a publicly traded national Internet service provider. At Cyberion, Mr. Madsen restructured the operations of the troubled company, successfully completed a private placement financing, achieved positive operating cash flow, and repackaged the company's consumer Internet assets for sale. While at Cyberion, Mr. Madsen initiated technology development on a secure Internet application that was spun out and ultimately sold by The DocSpace Company Inc. to Critical Path for $568 million.

Mr. Madsen previously worked in Commercial Banking with the Royal Bank of Canada in Edmonton. He has also been a member of the Investment Committee of ENSIS Investment Limited Partnership, a Canadian venture capital fund, and the Burrill AgBio Capital Fund, L.P. In addition, Mr. Madsen has served as a director of Biostar Inc., Idun Pharmaceuticals, Ltd. and has been a board observer on numerous biotechnology companies. Mr. Madsen currently is a Board Director for Elixir Pharmaceuticals, Surface Logix, and Chromatin. He holds the Chartered Financial Analyst designation and holds a Bachelor's degree in Commerce specializing in Finance from the University of Saskatchewan.

At Venrock, Dr. Roberts specializes in life sciences and healthcare internet areas. Dr. Roberts is primarily responsible for Venrock's investments in Illumina and Microbia, and serves on the board of athenahealth.com, First Genetic Trust, Surface Logix and Xenoport. Prior to joining Venrock, Bryan received his Ph.D. in Chemistry and Chemical Biology at Harvard University and from 1989-1992, he served as a corporate finance analyst in the investment banking department at Kidder Peabody & Co., Inc. Bryan graduated Phi Beta Kappa with high honors from Dartmouth College, where he obtained a B.A. in Chemistry.

Since 2007, Dr. Rubin has served as President and CEO of Titan, where he also sits on the Board of Directors. Prior to this, he was the Head of Global Research and Development at Bayer Schering Pharma, and a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Dr. Rubin trained in internal medicine at the Johns Hopkins Hospital, and in the sub specialties of Infectious Diseases and Oncology at the National Institutes of Health. He then served on the senior staff of the Infectious Diseases Section of the National Cancer Institute. Dr. Rubin joined Glaxo, Inc. (now GlaxoSmithKline and formerly GlaxoWellcome) in 1990 where he held various positions of increasing seniority prior to joining Schering AG in 2003 with responsibility for worldwide development. Dr. Rubin is board certified in internal medicine, oncology and infectious diseases. He received his MD from Cornell University Medical College in 1980.

Four years of experience in the pharma industry and six years of experience in investment management and research. Former senior biotechnology analyst at Bank Sarasin and department head at MDS Pharma Services; PhD in biotechnology from the Swiss Federal Institute of Technology, (ETH) Zurich; MSc in chemistry from the University of Groningen, the Netherlands.

Dr. Whitesides is a world leader in surface chemistry and drug design. He has received more than 25 professional recognitions and awards, including the 1998 National Medal of Science and the 2003 Kyoto Prize for Advanced Technology. Dr. Whitesides was a founder of several successful companies including GelTex Pharmaceuticals, Theravance, and Genzyme. Dr. Whitesides is also a member of several advisory panels including the National Science Foundation, Department of Defense, NASA, and the National Research Council. Dr. Whitesides is the author or co-author of more than 900 scientific publications. He received his Ph.D. from the California Institute of Technology in 1964 and was a faculty member at MIT from 1963 to 1982. He joined the Department of Chemistry of Harvard University in 1982 and was Chairman of the Department from 1986 to 1989 and Mallinckrodt Professor of Chemistry from 1982 to 2004.